Therapeutic Outcomes of Mycophenolate Mofetil and Three Other Immunosuppressants in Patients with Graves’ Ophthalmopathy

王坚,王扬天,邵加庆,赵明,王晓,杜宏

DOI: https://doi.org/10.3969/j.issn.1008-8199.2003.12.011

2003-01-01

Abstract:Objective:In this study, we analyzed the efficacy and tolerability of mycophenolate mofetil and three other immunosuppressants in Graves’ ophthalmopathy (GO) patients. Methods:Fifty four untreated GO patients were enrolled in this study. The diagnosis of GO was based on the presence of the typical clinical features and excluding of the possibility of cranial/orbital diseases, and the severity of ophthalmopathy was at least equal to or more severe than Class 2 in NO SPECS classification. Those who could afford were randomly assigned to receive either mycophenolate mofetil (MMF, n =12, 16～18 mg per kilogram per day) or cyclosporin A (CsA, n =11, 5～6 mg per kilogram of body weight per day) therapy. The others were randomly assigned to be given either prednisone ( n =16, finished in 13 case, 40 mg per day for 4 weeks, 20 mg for 4 weeks, and 10 mg for 4 weeks) or tripterygium multi glycosides (T Ⅱ , n =15, 30～60 mg per day). The disease severity and therapeutic response were quantitatively assessed according to the Ophthalmopathy Index Scoring System from Given wilson (1989) with sensibly modified. The improvement or progression of ophthalmopathy was defined if the variation, either increase or decrease of the score, reached 3 or more in the ophthalmopathy index. If this did not occur, a lack of response was indicated. In patients who had hyperthyroidism, antithyroid drugs were also administered.Results:After 12 week therapy, 7 (54 percent) of the 13 treated with prednisone improved, the remaining 6 (46 percent) lacked response. In T Ⅱ group, 10 (67 percent) of 15 responded to the therapy, 5 (33 percent) had no change. There was no significant difference in clinical response between the above 2 groups ( P 0.05). Five CsA treated and 11 MMF treated patients responded to therapy (45 percent vs 92 percent; P 0.05) . It seems that MMF is more effective than CsA in the treatment of GO although a significant decrease ( P 0.01) in the mean score of the CsA group has also been shown at the end of the course. None of all the 51 patients in the 4 groups had worsening of ophthalmopathy. Among 16 patients in prednisone group, 3 (19 percent) gained body weight by more than 5 percent, 2 (13 percent) developed impaired glucose tolerance (IGT). These two patients and one of the three weight gaining patients ceased the therapy. Impermanent menopause happened in 1 (11 percent) of the females in T Ⅱ group at the sixth month in sequel treatment after the course. Conclusion:MMF may be more effective than CsA in the treatment of Graves’ophthalmopathy. T Ⅱ may have a equal effectiveness and perhaps a better tolerability than prednisone in the immunotherapy of Graves’ ophthalmopathy.